Selective activation of androgen receptor to treat estrogen receptor positive breast cancer.

选择性激活雄激素受体治疗雌激素受体阳性乳腺癌。

• 批准号: nhmrc : 1084416
• 负责人: A/Pr Jason Carroll
• 金额: $ 56.23万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/selective-activation-androgen-breast-cancer/519004
• 关键词: Selective; activation; androgen; receptor; treat

A major challenge in breast cancer research is to find alternative drugs to treat women with drug-resistant disease. What’s new and exciting is a novel type of drug that mimics the ability of natural androgen hormones to inhibit estrogen action in breast cancers without undesirable masculinising side effects. This research will greatly facilitate the introduction of a new breast cancer treatment into clinics worldwide by the development of a new test that can predict response to this treatment.

乳腺癌研究中的一大挑战是寻找替代药物来治疗患有抗药性疾病的女性。新的和令人兴奋的是一种新型的药物，它模仿自然雄激素的能力，在没有不良的男性副作用的情况下抑制乳腺癌的雌激素作用。这项研究将极大地促进将一种新的乳腺癌治疗方法引入世界各地的临床，因为它开发了一种新的测试方法，可以预测这种治疗的反应。